Biapenem

Drugs

Volumn 62, Issue 15, 2002, Pages 2221-2234

  Perry, Caroline M ^a   Ibbotson, Tim ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; BIAPENEM; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFOTIAM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; DIHYDROPEPTIDASE I; IMIPENEM; MEROPENEM; OFLOXACIN; PANIPENEM; PENICILLIN DERIVATIVE; PEPTIDASE; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; AEROBIC BACTERIUM; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG STABILITY; DRUG TOLERABILITY; EOSINOPHILIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; JAPAN; LOWER RESPIRATORY TRACT INFECTION; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; TISSUE DISTRIBUTION; URINARY TRACT INFECTION; VOMITING;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0036032533     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262150-00005     Document Type: Review

References (68)

1. Yang Y, Testa RT, Bhachech N, et al. Biochemical characterization of novel tetrahydrofuranyl 1β-methylcarbapenems: Stability to hydrolysis by renal dehydropeptidases and bacterial β-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrob Agents Chemother 1999 Dec; 43 (12): 2904-9
2. Felici A, Perilli M, Segatore B, et al. Interactions of biapenem with active-site serine and metallo-β lactamases. Antimicrob Agents Chemother 1995 Jun; 39 (6): 1300-5
3. Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: Permeability, binding to penicillin-binding proteins, and stability to hydrolysis by βlactamases. J Antimicrob Chemother 1995 Jan; 35 (1): 75-84
4. Ubukata K, Sugiura M. Konno M. In vitro activity of biapenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 20-5
5. Kashitani F, Fukuzawa S, Mori C, et al. In vitro activities of carbapenem antibiotics against the various clinical isolates [abstract] [in Japanese]. Jpn J Antibot 2000 Jan; 53 (1): 25
6. Ubukata K, Chiba N, Kobayashi R, et al. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Chemother Jpn 2002 Jan; 50 (1): 1-10
7. Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992 Aug; 30: 129-34
8. Hikida M, Kawashima K, Nishiki K, et al. Renal dehydropeptidase-1 stability of LJC 10,627, a new carbapenem antibiotic. Antimicrob Agents Chemother 1992 Feb; 36 (2): 481-3
9. Sader HS, Gales AC. Emerging strategies in infectious diseases: New carbapenem and trinem antibacterial agents. Drugs 2001; 61 (5): 553-64
10. Day IP, Goudie J, Nishiki K, et al. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995 Apr; 76 (3): 239-43
11. Hikida M, Masukawa Y, Nishiki K, et al. Low neurotoxicity of LJC 10,627, a novel I beta-methyl carbapenem antibiotic: Inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993 Feb; 37 (2): 199-202
12. Hori S, Kanemitsu K, Shimada J. Relation between convulsant activity of biapenem, a new carbapenem, and its binding affinity to GABA receptor [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 115-20
13. Hoban DJ, Jones RN, Yamane N, et al. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1993 Nov 1993 31; 17 (4): 299-305
14. Igari J, Inoue M, Nishino T, et al. Survey of sensitivities of clinical isolates to antibacterial agents (annual report) [in Japanese]. Jpn J Antibiot 1997 Aug; 50 (8): 683-703
15. Igari J, Watanabe N, Uehara N, et al. Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents [in Japanese]. Jpn J Antibiot 2000 Mar; 53 (3): 157-70
16. Watanabe A, Kikuchi H, Kikuchi T, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years. J Infect Chemother 1999 Sep; 5 (3): 171-5
17. Suzuki Y, Nishinari C, Endo H, et al. Antimicrobial activities of carbapenems and forth generation cephems against clinically isolated strains [in Japanese]. Jpn J Antibiot 2001 Sep; 54 (9): 473-90
18. Catchpole CR, Wise R, Thomber D, et al. In vitro activity of L-627. A new carbapenem. Antimicrob Agents Chemother 1992 Sep; 36 (9): 1928-34
19. Bonfiglio G, Maccarone G, Mezzatesta ML, et al. In vitro activity of biapenem against recent gram-negative and gram-positive clinical isolates. Chemotherapy 1997 Nov 31; 43 (6): 393
20. Ubukata K, Hikida M, Yoshida M, et al. In vitro activity of LJC 10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother 1990 Jun; 34 (6): 994-1000
21. Malanoski GJ, Collins L, Wennersten C, et al. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 1993 Sep; 37 (9): 2009-16
22. Neu HC, Gu JW, Fang W, et al. In vitro activity and beta-lactamase stability of LJC 10,627. Antimicrob Agents Chemother 1992 Jul; 36 (7): 1418-23
23. Watanabe A, Tokue Y, Takahashi H, et al. In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998 [in Japanese]. Jpn J Antibiot 1999 Dec; 52 (12): 690-4
24. Yoshida M, Watanabe M, Mitsuhashi S. In vitro antibacterial activity of biapenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 1-19
25. Raymond NJ, Bremner DA. The in-vitro activity of biapanem against 964 clinical isolates of aerobic bacteria. J Antimicrob Chemother 1995 May; 35 (5): 681-6
26. Murase M. In vitro antibacterial activities of carbapenems against clinical isolates [in Japanese]. Jpn J Antibiot 1999 Nov; 52 (11): 667-79
27. Alonso R, Fernandez-Aranguiz A, Colom K, et al. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 1994 Oct: 13 (10): 820-2
28. Chen HY, Livermore DM. Comparative in-vitro activity of biapenem against enterobacteria with β-lactamase-mediated antibiotic resistance. J Antimicrob Chemother 1994 Mar; 33 (3): 453-64
29. Watanabe A, Tokue Y, Takahashi H, et al. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001 Dec; 7 (4): 267-71
30. Fujiue Y, Kuwabara M, Muroki K, et al. The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum [in Japanese]. Jpn J Antibiot 1998 Jan; 51 (1): 26-36
31. Hirakata Y, Matsuda J, Mochida C, et al. Annual changes is susceptibility of clinical isolates to biapenem [in Japanese]. Jpn J Chemother 2002; 50 (6): 329-51
32. Chen HY, Livermore DM. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J Antimicrob Chemother 1994 May; 33 (5): 949-58
33. Shibata K, Adachi Y, Kato E, et al. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa. J Antibiot (Tokyo) 1997 Feb; 50 (2): 135-8
34. Hikida M, Terashima S, Sato Y, et al. Comparative antibacterial activity of carbapenems againstP. aeruginosa (1) [in Japanese]. Jpn J Antibiot 2001 Nov; 54 (11): 571-9
35. Hikida M, Mori M, Kitta T. In vitro evaluation of biapenem, a new carbapenem antibiotic. Chemotherapy 1994 Dec; 42 (S-4): 101
36. Simor AE, Louie L, Louie M. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents [letter]. Eur J Clin Microbiol Infect Dis 1994 Jun; 13 (6): 521-3
37. Clarke AM, Zemcov SJV. Comparative in vitro activity of biapenem, a new carbapenem antibiotic. Eur J Clin Microbiol Infect Dis 1993; 12 (5): 377-84
38. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994 Apr; 38 (4): 898-900
39. Weiss WJ, Petersen PJ, Jacobus NV, et al. In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems. Antimicrob Agents Chemother 1999 Mar; 43 (3): 454-9
40. Chiba N, Kobayashi R, Hasegawa K. Activity of biapenem and 7 other antimicrobial agents against Streptococcus pneumoniae [in Japanese]. Jpn J Chemother 2002 Mar; 50 (3): 161-70
41. Saito A, Inamatsu T, Okada T, et al. Committee Report: Clinical breakpoints in pulmonary infections and sepsis: New antimicrobial agents and supplemental information for some agents already released [in Japanese]. J Infect Chemother 1999; 5 (4): 223-6
42. Aldridge KE, Morice N, Schiro DD. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 1994 Apr; 38 (4): 889-93
43. Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano-Martin I, et al. L-627, a novel carbapenem: In-vitro activity against anaerobes [letter]. J Antimicrob Chemother 1994 Jan; 33 (1): 183-6
44. Wexler HM, Molitoris E, Finegold SM. The in-vitro activity of L-627 against anaerobic bacteria. J Antimicrob Chemother 1994 Mar; 33 (3): 629-34
45. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500. biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993 Aug; 32 (2): 223-31
46. Nord CE, Lindmark A, Persson I. In vitro activity of L-627 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1992 Aug; 11 (8): 757-60
47. Miyake Y, Fujiwara S, Usui T, et al. In vitro antibacterial activity of biapenem against adherent bacteria [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 82-90
48. Hiraishi T, Miyata A, Hara T, et al. Bactericidal activity of biapenem against various bacteria [in Japanese]. Jpn J Antibiot 2001 Dec; 54 (12): 581-95
49. Hiraishi T, Miyata A, Takata T. Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa [in Japanese]. Jpn J Antibot 2002 Feb; 55 (1): 76
50. Hikida M, Yamazaki Y, Yoshida M, et al. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa. J Antibiot (Tokyo) 1995 Aug; 48 (8): 891-2
51. Houston AK, Jones RN. Post-antibiotic effect of FK-037 and biapenem tested against five bacterial species. J Chemother 1994 Feb; 6 (1): 12-4
52. Nakashima M, Uematsu T, Ueno K, et al. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int J Clin Pharmacol Ther Toxicol 1993 Feb; 31 (2): 70-6
53. Tarao F, Miura T, Saito A, et al. Pharmacokinetic study of biapenem [in Japanese]. Jpn J Chemother 1996; 44 (10): 769-75
54. Nagashima S, Kozawa O, Otsuka T, et al. Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis. J Antimicrob Chemother 2000 Nov; 46 (5): 839-42
55. Kozawa O, Uematsu T, Matsuno H, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother 1998 Jun; 42 (6): 1433-6
56. Meiji. Omegacin® (biapenem) Prescribing Information [in Japanese]. Kanagawa, Japan: Meiji, 2002
57. Koeppe P, Hoffler D, Fitzen B. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneimittelforschung 1997 Nov; 47 (11): 1250-6
58. Mori M, Hikida M, Nishihara T, et al. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydro-peptidase-I. J Antimicrob Chemother 1996 May; 37: 1034-6
59. Brismar B, Akerlund JE, Sjostedt S, et al. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: Report from a Swedish Study Group. Scand J Infect Dis 1996; 28 (5): 507-12
60. Matsumoto F, Inoue M, Sakurai I, et al. Dose-comparison study on biapenem in the treatment of chronic bronchitis [in Japanese]. Jpn J Chemother 2000; 48 (1): 34-44
61. Matsumoto F, Inoue M, Sakurai I, et al. A comparative study of biapenem and imipemem/cilastafin in lower respiratory infections [in Japanese]. Jpn J Chemother 2000; 48 (1): 45-67
62. Matsumoto F, Imai T, Sakurai I, et al. A comparative study of biapenem and imipenem/cilastatin for chronic respiratory tract infection [in Japanese]. Jpn J Chemother 1995; 43 (1): 63-84
63. Matsumoto F, Imai T, Sakurai I, et al. A comparative study of biapenem and imipenem/cilastatin for bacterial pneumonia [in Japanese]. Jpn J Chemother 1995; 43 (1): 41-62
64. Kawada Y, Deguchi T, Kumamoto Y, et al. Comparative study on biapenem and imipenem/cilastatin in complicated urinary tract infection [in Japanese]. Chemotherapy 1994; 42 (12): 1368-84
65. Kawada Y, Deguchi T, Tsukamoto T, et al. Comparative study on biapenem and imipenem/cilastatin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2000; 48 (3): 218-32
66. Kawada Y, Deguchi T, Kawabe K, et al. Dose-finding study of biapenem in complicated urinary tract infections [in Japanese]. Jpn J Chemother 1999; 47 (12): 852-62
67. Hara K, Baba S, Matsumoto F, et al. Clinical evaluation of biapenem in various infectious diseases [in Japanese]. Jpn J Antibiot 1999 Nov; 52 (11): 629-60
68. Baba S, Miyamoto N, Ichikawa G, et al. Laboratory and clinical findings on L-627 (biapenem) in otorhinolaryngological infections [in Japanese]. Jibi To Rinsho 1995; 41 (No. 3): 495-509